A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study will explore the combination of the oral drug PF-00299804 and intravenous
CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given
separately to patients in prior studies, and this study is to establish the safety and
efficacy of the combination.